iBio (IBIO) director receives 60,000 stock options vesting over 3 years

Rhea-AI Filing Summary

iBio, Inc. director Elizabeth Stoner received a grant of stock options covering 60,000 shares of common stock. The options have an exercise price of 1.42 per share and expire on 2036-05-17. They vest monthly on a pro rata basis over 36 months, and following this award she holds 60,000 options in total.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Stoner Elizabeth

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	60,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 60,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 60,000 options Exercise price: 1.42 per share Underlying shares: 60,000 shares +3 more

6 metrics

Options granted 60,000 options Stock Option (right to buy) granted to director

Exercise price 1.42 per share Exercise price for the stock option grant

Underlying shares 60,000 shares Common stock underlying the option

Expiration date 2036-05-17 Option expiration for this grant

Vesting period 36 months Vests monthly on a pro rata basis

Options after transaction 60,000 options Total derivative securities following the grant

Key Terms

Stock Option (right to buy), derivative, exercise price, vesting monthly, +1 more

5 terms

Stock Option (right to buy) financial

"security title is listed as Stock Option (right to buy)"

derivative financial

"transaction type is classified as derivative"

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

exercise price financial

"conversion or exercise price is reported as 1.4200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting monthly financial

"footnote states Vesting monthly on a pro rata basis over 36 months"

expiration date financial

"expiration date is disclosed as 2036-05-17"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stoner Elizabeth

(Last) (First) (Middle)

C/O IBIO, INC.

11750 SORRENTO VALLEY ROAD, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
iBio, Inc. [ IBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.42	05/18/2026		A		60,000		(1)	05/17/2036	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. Vesting monthly on a pro rata basis over 36 months.

	/s/ Marc Banjak, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did iBio (IBIO) director Elizabeth Stoner report on this Form 4?

Elizabeth Stoner reported receiving a stock option grant for 60,000 shares of iBio common stock. The award is a compensation-related grant, not an open-market stock purchase or sale, and is reflected as a derivative security position.

What are the key terms of Elizabeth Stoner’s iBio stock option grant?

The option covers 60,000 underlying shares of iBio common stock with an exercise price of 1.42 per share. It is structured as a derivative security granting the right to buy shares at this fixed exercise price in the future.

How do the iBio stock options granted to Elizabeth Stoner vest?

The stock options vest monthly on a pro rata basis over 36 months. This means a portion of the 60,000 options becomes exercisable each month during the three-year vesting period, rather than all vesting at once on a single date.

When do Elizabeth Stoner’s iBio stock options expire?

The options expire on 2036-05-17, giving a long exercise window. After that expiration date, any unexercised options will lapse and no longer provide the right to buy iBio common stock at the 1.42 exercise price.

How many iBio options does Elizabeth Stoner hold after this transaction?

Following this grant, Elizabeth Stoner holds 60,000 stock options in total. The Form 4 shows total derivative securities following the transaction equal to 60,000, indicating this award establishes her reported option position at that level.